Clearproof Spot Solution for Acne-Prone Skin

Description

Clear Proof is a spot solution formulated specifically for acne-prone skin. The product is presented in a 29 g dosage form, designed for targeted application to address localized acne concerns.

Uses and Indications

This drug is indicated for the treatment of acne-prone skin as a spot solution.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The product should be applied directly to the affected areas as needed. During the initial three days of treatment, it is recommended to apply the product sparingly to one or two small, affected areas. If no discomfort is experienced following this initial application, healthcare professionals may continue to follow the aforementioned directions for subsequent applications.

Contraindications

The product is contraindicated for use in children under 3 years of age. Additionally, direct contact with the eyes should be avoided. In the event of contact with the eyes, it is essential to rinse thoroughly with water.

Warnings and Precautions

The use of this product is contraindicated in children under 3 years of age. Healthcare professionals should ensure that this medication is not administered to this age group to prevent potential adverse effects.

Direct contact with the eyes must be strictly avoided. In the event that the product inadvertently comes into contact with the eyes, it is imperative to rinse the affected area thoroughly with water to mitigate any potential irritation or damage.

Healthcare providers are advised to educate patients and caregivers on these precautions to ensure safe and effective use of the product.

Side Effects

Patients should be aware of the following warnings associated with the use of this product. It is contraindicated for children under 3 years of age. Additionally, direct contact with the eyes should be avoided. In the event that the product comes into contact with the eyes, it is imperative to rinse thoroughly with water to mitigate any potential adverse effects.

No specific adverse reactions have been reported in clinical trials or postmarketing experiences; however, adherence to the warnings is essential to ensure patient safety.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Clearproof Spot Solution for Acne-Prone Skin (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 3 years of age should not use this medication. Safety and efficacy have not been established in this age group, and caution is advised when considering treatment options for younger children.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

The safety of this medication during pregnancy has not been specifically established. There are no available data regarding the potential risks or fetal outcomes associated with its use in pregnant patients. Healthcare professionals should exercise caution when prescribing this medication to women of childbearing potential. It is advisable to weigh the potential benefits against any unknown risks to the fetus. Further studies may be necessary to fully understand the implications of this medication during pregnancy.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, respiratory depression, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the clinical scenario and the substance involved. Consultation with a poison control center or a medical toxicologist is recommended to guide management decisions and ensure optimal patient care.

Overall, vigilance and prompt intervention are critical in managing cases of suspected overdose, even in the absence of detailed information regarding specific overdosage effects.

Nonclinical Toxicology

No relevant information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no pertinent data concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to apply the product directly to the affected areas as needed. It is recommended that patients apply the product sparingly to one or two small, affected areas during the first three days of use. If no discomfort occurs, patients may continue to follow the previously stated directions.

Providers should emphasize that the product is not to be used in children under three years of age. Additionally, patients should be cautioned to avoid direct contact with the eyes. In the event that the product does get into the eyes, patients should rinse thoroughly with water.

Storage and Handling

The product is supplied in a tube format, with specific handling and storage requirements to ensure its integrity and effectiveness. It should be stored at room temperature, away from direct light exposure. To maintain the product's quality, it is essential to keep the tube tightly closed when not in use. Additionally, any unused product should be discarded after opening if it is not utilized within a specified time frame.

Additional Clinical Information

The route of administration for the product is topical. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Clearproof Spot Solution for Acne-Prone Skin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)